April 2026
M	T	W	T	F	S	S
	1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30

Federica Fogacci: Lp(a) Doesn’t Simply Add Risk – It Reframes Risk

Federica Fogacci/LinkedIn

Dec 22, 2025, 12:31

Federica Fogacci: Lp(a) Doesn’t Simply Add Risk – It Reframes Risk

Federica Fogacci, Editorial Board member and Social Media Editor at Atherosclerosis, shared on LinkedIn:

“Lp(a) doesn’t simply add risk. It reframes risk. For patients, it can turn a test result into a long-term insight—and, at times, a family story.

That’s why “should we test?” is no longer the real question. The real question is whether we can implement Lp(a) testing in a way that is clear, useful, and supportive. Elevated Lp(a) is common and consistently linked to major cardiovascular outcomes, yet measurement is still far from routine. In our new Journal of Clinical Lipidology editorial (with Arrigo F.G. Cicero and Peter Libby), we argue it’s no longer a dilemma. It’s a mandate.

But a mandate without a patient-centred pathway is just a number on a report. If we want Lp(a) testing to matter, we need to make the experience work for real people: communication that informs without alarming, a clear “what next,” and support for family conversations—including cascade screening when appropriate.

This is also where alignment is possible. Clinicians can normalise when and how to measure Lp(a) and how to frame results. Patient organisations can help ensure the message lands in a way that empowers rather than overwhelms. And researchers and industry can translate this momentum into scalable pathways—and, ultimately, better options for care.”

Title: Lipoprotein(a)—To test or not to test, not a dilemma but a mandate

Authors: Federica Fogacci, Peter Libby, Arrigo Francesco Giuseppe Cicero

Federica Fogacci: Lp(a) Doesn’t Simply Add Risk - It Reframes Risk